600521 华海药业
已收盘 09-04 15:00:00
资讯
新帖
简况
股市必读：华海药业新发布《浙江华海药业股份有限公司关于获得药品注册证书的公告》
证券之星 · 08-31
股市必读：华海药业新发布《浙江华海药业股份有限公司关于获得药品注册证书的公告》
每周股票复盘：华海药业（600521）Q2净利增227.2%
证券之星 · 08-30
每周股票复盘：华海药业（600521）Q2净利增227.2%
华海药业（600521）披露2026年半年度募集资金存放、管理与实际使用情况的专项报告，8月27日股价上涨1.46%
证券之星 · 08-27
华海药业（600521）披露2026年半年度募集资金存放、管理与实际使用情况的专项报告，8月27日股价上涨1.46%
华海药业最新公告：2026年半年度净利润同比增长88.26%
证券之星 · 08-26
华海药业最新公告：2026年半年度净利润同比增长88.26%
每周股票复盘：华海药业（600521）子公司通过药品GMP符合性检查
证券之星 · 08-23
每周股票复盘：华海药业（600521）子公司通过药品GMP符合性检查
华海药业：子公司通过药品GMP符合性检查
格隆汇 · 08-19
华海药业：子公司通过药品GMP符合性检查
华海药业：子公司获得富马酸伏诺拉生片药品注册证书
格隆汇 · 08-07
华海药业：子公司获得富马酸伏诺拉生片药品注册证书
8月7日华海药业涨6.62%，湘财医药健康混合A基金重仓该股
证券之星 · 08-07
8月7日华海药业涨6.62%，湘财医药健康混合A基金重仓该股
华海药业（600521）披露公司产品拟中选第十二批全国药品集中采购，8月3日股价上涨0.3%
证券之星 · 08-03
华海药业（600521）披露公司产品拟中选第十二批全国药品集中采购，8月3日股价上涨0.3%
华海药业最新公告：四款产品拟中选第十二批国家药品集采
证券之星 · 08-02
华海药业最新公告：四款产品拟中选第十二批国家药品集采
华海药业最新公告：子公司盐酸贝尼地平片获药品注册证书
证券之星 · 07-30
华海药业最新公告：子公司盐酸贝尼地平片获药品注册证书
华海药业（600521）披露子公司获得药品注册批准公告，7月29日股价上涨1.43%
证券之星 · 07-29
华海药业（600521）披露子公司获得药品注册批准公告，7月29日股价上涨1.43%
华海药业(600521.SH)：瑞西奇拜单抗注射液获得药品注册批准
智通财经 · 07-29
华海药业(600521.SH)：瑞西奇拜单抗注射液获得药品注册批准
华海药业：子公司瑞西奇拜单抗注射液获批上市
格隆汇 · 07-29
华海药业：子公司瑞西奇拜单抗注射液获批上市
每周股票复盘：华海药业（600521）获琥珀酸亚铁片注册证
证券之星 · 07-26
每周股票复盘：华海药业（600521）获琥珀酸亚铁片注册证
华海药业(600521.SH)子公司获注射用HB0043新增皮下注射给药途径临床试验许可
智通财经 · 07-24
华海药业(600521.SH)子公司获注射用HB0043新增皮下注射给药途径临床试验许可
华海药业最新公告：琥珀酸亚铁片获药品注册证书
证券之星 · 07-23
华海药业最新公告：琥珀酸亚铁片获药品注册证书
每周股票复盘：华海药业（600521）出售金融资产获净利3512万
证券之星 · 07-19
每周股票复盘：华海药业（600521）出售金融资产获净利3512万
华海药业获得发明专利授权：“一种精制左旋多巴的方法”
证券之星 · 07-18
华海药业获得发明专利授权：“一种精制左旋多巴的方法”
华海药业汛桥基地收到FDA“问题清单”，涉及13项生产缺陷
蓝鲸财经 · 07-15
华海药业汛桥基地收到FDA“问题清单”，涉及13项生产缺陷
加载更多
公司概况
公司名称：
浙江华海药业股份有限公司
所属行业：
医药制造业
上市日期：
2003-03-04
主营业务：
浙江华海药业股份有限公司的主营业务是多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。公司的主要产品是心血管类原料药、精神障碍类原料药、神经系统类原料药、抗感染类原料药、消化类治疗药、呼吸类治疗药、抗肿瘤类治疗药、内分泌类治疗药。
发行价格：
15.55
{"stockData":{"symbol":"600521","market":"SH","secType":"STK","nameCN":"华海药业","latestPrice":15.99,"timestamp":1788505200000,"preClose":16.11,"halted":0,"volume":18587700,"delay":0,"changeRate":-0.0074,"floatShares":1497000000,"shares":1497000000,"eps":0.4194,"marketStatus":"已收盘","change":-0.12,"latestTime":"09-04 15:00:00","open":16.1,"high":16.17,"low":15.96,"amount":299000000,"amplitude":0.013,"askPrice":15.99,"askSize":17,"bidPrice":15.98,"bidSize":537,"shortable":0,"etf":0,"ttmEps":0.4194,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":5,"adr":0,"adjPreClose":16.11,"symbolType":"stock","openAndCloseTimeList":[[1788485400000,1788492600000],[1788498000000,1788505200000]],"highLimit":17.72,"lowLimit":14.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1497252196,"isCdr":false,"pbRate":2.51,"roa":"--","peRate":38.125894,"roe":"7.92%","epsLYR":0.18,"committee":0.462606,"marketValue":23941000000,"turnoverRate":0.0124,"status":1,"floatMarketCap":23941000000},"requestUrl":"/m/hq/s/600521","defaultTab":"news","newsList":[{"id":"2663198042","title":"股市必读：华海药业新发布《浙江华海药业股份有限公司关于获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663198042","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663198042?lang=zh_cn&edition=full","pubTime":"2026-08-31 02:14","pubTimestamp":1788113651,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，华海药业报收于16.46元，下跌1.08%，换手率1.46%，成交量21.9万手，成交额3.6亿元。公司公告汇总浙江华海药业股份有限公司关于获得药品注册证书的公告浙江华海药业股份有限公司下属全资子公司浙江华海制药科技有限公司近日收到国家药品监督管理局核准签发的利奥西呱片《药品注册证书》，规格为0.5mg、1mg、2.5mg，注册分类为化学药品4类，审批结论为符合药品注册要求，批准注册。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100000740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0028","BK0012","BK0188","BK0239","BK0201","600521","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010615","title":"每周股票复盘：华海药业（600521）Q2净利增227.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010615","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663010615?lang=zh_cn&edition=full","pubTime":"2026-08-30 02:25","pubTimestamp":1788027910,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，华海药业报收于16.46元，较上周的16.62元下跌0.96%。本周，华海药业8月27日盘中最高价报16.88元。华海药业当前最新总市值246.45亿元，在化学制药板块市值排名16/149，在两市A股市值排名807/5211。第二季度单季主营收入25.77亿元，同比上升20.0%；单季度归母净利润3.67亿元，同比上升227.2%；单季度扣非净利润2.9亿元，同比上升267.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000000828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0070","600521","BK0188","BK0012","BK0185","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662011587","title":"华海药业（600521）披露2026年半年度募集资金存放、管理与实际使用情况的专项报告，8月27日股价上涨1.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662011587","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662011587?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:22","pubTimestamp":1787829738,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，华海药业报收于16.64元，较前一交易日上涨1.46%，最新总市值为249.14亿元。公司于近日披露《浙江华海药业股份有限公司关于2026年半年度募集资金存放、管理与实际使用情况的专项报告》。公告显示，2020年可转债募集资金已全部使用完毕，相关账户已注销。向特定对象发行股票的募集资金净额58,231.94万元，截至2026年6月30日余额为17,344.05万元。闲置募集资金用于现金管理及暂时补充流动资金均按规定执行，无违规情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700045594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0239","600521","BK0012","BK0201","BK0070","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662671304","title":"华海药业最新公告：2026年半年度净利润同比增长88.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662671304","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662671304?lang=zh_cn&edition=full","pubTime":"2026-08-26 19:18","pubTimestamp":1787743124,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称，公司发布2026年半年度报告，实现营业收入49.13亿元，同比增长8.78%；归属于上市公司股东的净利润7.71亿元，同比增长88.26%。注：公司Q2净利润3.67亿，之前预告区间为3.52亿-3.94亿，Q1净利润4.04亿，据此计算，Q2净利润环比下降9%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600043384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661211510","title":"每周股票复盘：华海药业（600521）子公司通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2661211510","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661211510?lang=zh_cn&edition=full","pubTime":"2026-08-23 01:18","pubTimestamp":1787419091,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，华海药业报收于16.62元，较上周的17.53元下跌5.19%。本周，华海药业8月20日盘中最高价报17.93元。本周关注点公司公告汇总：子公司通过药品GMP符合性检查，涉及瑞西奇拜单抗注射液及氢溴酸伏硫西汀产线公司公告汇总浙江华海药业股份有限公司下属子公司浙江华海生物科技有限公司、上海华奥泰生物药业股份有限公司、浙江华海建诚药业有限公司通过药品GMP符合性检查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600521","BK0028","BK0070","BK0188","BK0239","BK0185","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660371441","title":"华海药业：子公司通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2660371441","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660371441?lang=zh_cn&edition=full","pubTime":"2026-08-19 17:50","pubTimestamp":1787133029,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","600521","BK0028","BK0188","BK0201","BK0185","BK0012","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657619216","title":"华海药业：子公司获得富马酸伏诺拉生片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2657619216","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657619216?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:23","pubTimestamp":1786094624,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0185","BK0239","600521","BK0012","BK0201","BK0070","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657615752","title":"8月7日华海药业涨6.62%，湘财医药健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657615752","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657615752?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:36","pubTimestamp":1786091800,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日华海药业涨6.62%，收盘报17.55元，换手率4.81%，成交量72.04万手，成交额12.36亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为湘财基金的湘财医药健康混合A。湘财医药健康混合A目前规模为0.48亿元，最新净值1.7084，较上一交易日下跌0.25%，近一年上涨3.49%。湘财医药健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0070","BK0185","BK0012","BK0188","600521","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656832749","title":"华海药业（600521）披露公司产品拟中选第十二批全国药品集中采购，8月3日股价上涨0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656832749","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656832749?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:46","pubTimestamp":1785750370,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，华海药业报收于16.77元，较前一交易日上涨0.3%，最新总市值为251.09亿元。近日，浙江华海药业股份有限公司发布《关于公司产品拟中选第十二批全国药品集中采购的公告》。采购周期自中选结果执行之日起至2029年12月31日。拉莫三嗪片2025年国内销售额约4,037.71万元，占当年营收0.47%；2026年一季度销售额约975.30万元，占当季营收0.42%。其余三款产品于2026年上半年获批，截至2026年一季度末尚未产生销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300024180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0201","600521","BK0188","BK0239","BK0070","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656312296","title":"华海药业最新公告：四款产品拟中选第十二批国家药品集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2656312296","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656312296?lang=zh_cn&edition=full","pubTime":"2026-08-02 16:01","pubTimestamp":1785657689,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称，公司参加第十二批全国药品集中采购，拉莫三嗪片、艾拉莫德片、培哚普利氨氯地平片(III)、美沙拉秦肠溶片拟中选。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200005798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0201","BK0012","BK0188","600521","BK0070","BK0185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655820439","title":"华海药业最新公告：子公司盐酸贝尼地平片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2655820439","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655820439?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:56","pubTimestamp":1785405399,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称，公司子公司近日收到国家药监局核准签发的盐酸贝尼地平片《药品注册证书》，该药品用于治疗原发性高血压、心绞痛，按化学药品4类批准生产视同通过一致性评价。2025年国内市场销售金额约11.72亿元，公司研发投入约707万元。该产品获批将进一步丰富公司产品线，提升市场竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000028471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0185","BK0201","BK0239","BK0070","BK0028","600521","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655540899","title":"华海药业（600521）披露子公司获得药品注册批准公告，7月29日股价上涨1.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655540899","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655540899?lang=zh_cn&edition=full","pubTime":"2026-07-29 22:19","pubTimestamp":1785334754,"startTime":"0","endTime":"0","summary":"截至2026年7月29日收盘，华海药业报收于16.27元，较前一交易日上涨1.43%，最新总市值为243.6亿元。该股当日开盘16.11元，最高16.44元，最低15.94元，成交额达4.53亿元，换手率为1.86%。近日，浙江华海药业股份有限公司公告，其控股子公司上海华奥泰生物药业股份有限公司申报的瑞西奇拜单抗注射液已获国家药品监督管理局批准上市，用于治疗成人泛发性脓疱型银屑病发作。截至目前，项目研发投入约2.59亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900040470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521","BK0070","BK0012","BK0028","BK0185","BK0201","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655893617","title":"华海药业(600521.SH)：瑞西奇拜单抗注射液获得药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655893617","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655893617?lang=zh_cn&edition=full","pubTime":"2026-07-29 21:01","pubTimestamp":1785330066,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华海药业 发布公告，近日，公司从国家药品监督管理局网站获悉，国家药品监督管理局通过优先审评审批程序批准上海华奥泰生物药业股份有限公司申报的瑞西奇拜单抗注射液上市，用于治疗成人泛发性脓疱型银屑病发作。瑞西奇拜单抗注射液作为国内首个自研创新抗IL-36R抗体，可通过抑制IL-36通路发挥抗炎的生物学效应。截至目前，公司在瑞西奇拜单抗注射液项目上的研发投入合计约人民币25,915万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华海药业(600521.SH)：瑞西奇拜单抗注射液获得药品注册批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0239","BK0201","BK0188","600521","BK0185","BK0028","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655862895","title":"华海药业：子公司瑞西奇拜单抗注射液获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2655862895","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655862895?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:19","pubTimestamp":1785323956,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0188","BK0201","BK0012","BK0185","BK0239","BK0028","600521","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654953052","title":"每周股票复盘：华海药业（600521）获琥珀酸亚铁片注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2654953052","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654953052?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:18","pubTimestamp":1784999893,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，华海药业报收于16.01元，较上周的16.15元下跌0.87%。本周，华海药业7月22日盘中最高价报17.38元。本周关注点公司公告汇总：华海药业获琥珀酸亚铁片药品注册证书，视同通过一致性评价。公司公告汇总浙江华海药业股份有限公司近日收到国家药品监督管理局核准签发的琥珀酸亚铁片《药品注册证书》，药品批准文号为国药准字H20265277，注册分类为化学药品3类。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0012","600521","BK0188","BK0185","BK0070","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653083394","title":"华海药业(600521.SH)子公司获注射用HB0043新增皮下注射给药途径临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2653083394","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653083394?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:38","pubTimestamp":1784885932,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华海药业 发布公告，近日，公司下属子公司上海华奥泰生物药业股份有限公司和华博生物医药技术(上海)有限公司收到国家药品监督管理局核准签发的注射用HB0043项目新增皮下注射给药途径的《药物临床试验批准通知书》。据悉，HB0043为全球首款双抗药物，同时靶向白细胞介素-17A和白细胞介素-36受体，具有高结合和阻断活性，开发用于治疗多种难以治疗的自身免疫性疾病，有望突破现有单靶点治疗的局限。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0201","MDTX","BK0012","BK0188","PSYK","600521","BK0070","BK0185","BK0239","IBBQ","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653670746","title":"华海药业最新公告：琥珀酸亚铁片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2653670746","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653670746?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:06","pubTimestamp":1784801199,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称，公司近日收到国家药监局核准签发的琥珀酸亚铁片《药品注册证书》，该药品用于缺铁性贫血的预防和治疗，按化学药品3类批准生产可视同通过一致性评价。2025年该药品国内市场销售金额约4.08亿元，公司研发投入约515万元。此次获批将进一步丰富公司产品线，提升市场竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300037311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0239","BK0201","BK0028","600521","BK0188","BK0070","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652237159","title":"每周股票复盘：华海药业（600521）出售金融资产获净利3512万","url":"https://stock-news.laohu8.com/highlight/detail?id=2652237159","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652237159?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:31","pubTimestamp":1784395868,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，华海药业报收于16.15元，较上周的16.84元下跌4.1%。本周，华海药业7月16日盘中最高价报17.8元。公司公告汇总浙江华海药业股份有限公司于2026年6月26日召开董事会，授权管理层在12个月内择机出售公司持有的金融资产。截至2026年7月13日，公司通过集中竞价交易方式累计出售共同药业和盟科药业股票，成交金额约10,744.98万元，占公司2025年度净资产的1.14%；累计产生净利润约3,512.44万元，占2025年度净利润的13.18%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0070","BK0012","BK0201","BK0239","600521","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652287244","title":"华海药业获得发明专利授权：“一种精制左旋多巴的方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2652287244","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652287244?lang=zh_cn&edition=full","pubTime":"2026-07-18 03:22","pubTimestamp":1784316141,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示华海药业新获得一项发明专利授权，专利名为“一种精制左旋多巴的方法”，专利申请号为CN202110705840.8，授权日为2026年7月17日。该精制方法适用于规模化生产，所得左旋多巴具有良好的晶体形态。今年以来华海药业新获得专利授权17个，较去年同期增加了70%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071800001641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0201","BK0028","BK0188","BK0012","600521","BK0185","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651451582","title":"华海药业汛桥基地收到FDA“问题清单”，涉及13项生产缺陷","url":"https://stock-news.laohu8.com/highlight/detail?id=2651451582","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651451582?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:51","pubTimestamp":1784109072,"startTime":"0","endTime":"0","summary":"图片来源：FDA官网蓝鲸新闻7月15日讯根据美国食品药品监督管理局在2026年7月13日披露的信息，华海药业位于临海的汛桥生产基地收到了一份FDA 483检查观察表，其中列出了13大类生产缺陷，覆盖多个关键质量环节。FDA于2018年9月对华海药业某生产基地发布进口禁令，暂停该基地生产的原料药及相关制剂进入美国市场；EMA也认定该生产基地未能充分遵守GMP要求，禁止其生产的缬沙坦原料药进入欧盟市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1784108798667662113","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4585","BK0012","BK0239","BK0201","BK0028","BK4588","600521","LABU","BK0188","BK0070","BK0185"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788520029787,"stockEarnings":[{"period":"1week","weight":-0.0319},{"period":"1month","weight":-0.0546},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.0145},{"period":"1year","weight":-0.3971},{"period":"ytd","weight":-0.044}],"compareEarnings":[{"period":"1week","weight":-0.0037},{"period":"1month","weight":0.0313},{"period":"3month","weight":-0.0213},{"period":"6month","weight":-0.0442},{"period":"1year","weight":0.0337},{"period":"ytd","weight":-0.0067}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江华海药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"83272人(较上一季度减少6.79%)","perCapita":"17980股","listingDate":"2003-03-04","address":"浙江省台州市临海市汛桥镇汛大路88号","registeredCapital":"149725万元","survey":" 浙江华海药业股份有限公司的主营业务是多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。公司的主要产品是心血管类原料药、精神障碍类原料药、神经系统类原料药、抗感染类原料药、消化类治疗药、呼吸类治疗药、抗肿瘤类治疗药、内分泌类治疗药。","listedPrice":15.55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华海药业(600521)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华海药业,600521,华海药业股票,华海药业股票老虎,华海药业股票老虎国际,华海药业行情,华海药业股票行情,华海药业股价,华海药业股市,华海药业股票价格,华海药业股票交易,华海药业股票购买,华海药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华海药业(600521)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}